Closely-held Rubius Therapeutics appointed Andrew Oh, who has more than 20 years of experience in finance and the biopharmaceutical industry, as CFO.
Prior to joining Rubius, Mr. Oh served as chief investment officer and chief operating officer at Leerink Pharmaceutical Investments, a subsidiary of Leerink Capital Partners. Prior to Leerink, he was a senior analyst covering global pharmaceutical companies and was a portfolio manager at Fidelity Investments.
“Andrew’s career-long experience as an investor and analyst at some of the best financial institutions, coupled with his extensive network in the global biopharmaceutical community make him an excellent addition to the Rubius team as the company continues to grow and work to advance the next generation of cellular therapies,” Torben Nissen, president of Rubius, said in a statement.
Mr. Oh said Rubius has the potential to transform care for people suffering from a broad range of serious diseases, by pioneering the next generation of cellular therapies and the development of breakthrough therapies for patients in need.
